CV Science

Catherine Brenner Mitochondria, Metabolism and Cell Death in Physiopathology

Course and current status

Education

1999 : Habilitation à diriger des recherches, University of Technology of Compiègne, France

1994 : Ph.D. University of Rennes I, France, Biochemistry and Cell Biology (H. Wroblewski)

Appointments/affiliations

2020 : Unit Director, CNRS-University of Paris Saclay-GUSTAVE ROUSSY UMR, Metabolis and systemic asprects of oncogenesis for new therapeutic approaches (METSY)

2019 : External scientific evaluator for FNRS (Belgium)

2016-2026 : Member of the National Comitee of CNRS, section 24

2014-present : Scientific Director, assay developpment and high throughput screening facility CIBLOT, IPSIT, Châtenay-Malabry (http://www.ipsit.ifr141.u-psud.fr/fr/page/plateformes/16-ciblot.html).

2010-2019: Research Director, INSERM UMR-S 1180, Labex LERMIT, Châtenay-Malabry, University of Paris Sud. Team 2: Cyclic nucleotide signaling and cardiac and vascular pathophysiology (G. Vandecasteele, R. Fischmeister).

2002-2010 : Researcher, CNRS UMR 8159, University of Versailles, France (B. MIgnotte)

1998-2002 : Lecturer, University of Technology of Compiègne, France (D. Thomas)

1998: Post-doctoral Fellow, INSERM, Paul Brousse hospital, Villejuif, France (G. Kroemer)

1994-1997: Post-doctoral Fellow, Institut Pasteur, Paris, France (L. Montagnier)

Scientific summary

Research interests: Catherine Brenner's research interests are centered on Mitochondria, Metabolism and cell death in pathophysiology.

In 1998, she discovered the cooperation of Bax and ANT in mitochondrial apoptosis and until 2010, she investigated the role of the permeability transition pore, a mitochondrial polyprotein complex, as a target for anti-cancer chemotherapy.

Since 2010, her research interests focus also on the role of mitochondria in signalisation and cardiac pathophysiology and the search for novel strategies in cardioprotection. 

Recent projects: In 2013-2014, she was co-coordinator of the Labex LERMIT project  "New therapeutic targets to treat Heart Failure". The aim was to identify new drug candidates targeting the phosphodiesterase PDE2A and the mitochondrial adenine nucleotide transloace ANT1 by screening large chemical libraries. This interdisciplinary project involved partners from CEA-DSV Saclay, ICSN Gif Sur Yvette, BioCis Chatenay-Malabry, and CIBLOT facility, Châtenay-Malabry, France. www.labex-lermit.fr 

2014-2017, she was the coordinator of an ANR CardioBDP project to disclose the cardioprotective mechanisms of berries driven polyphenols.http://www.agence-nationale-recherche.fr/en/anr-funded-project/?tx_lwmsuivibilan_pi2[CODE]=ANR-13-ISV1-0001

Since 2015, she co-coordinates iCROC, a Labex LERMIT project, to find molecules to improve the efficacy of radiotherapy and prevent cardiotoxicity. This multidisciplinary project involves biologists and radiobiologists from IGR hospital, Villejuif and chemists from CEA DSV, UNiversity of Paris Saclay (http://www.labex-lermit.fr/fr/recherche/projets/cibles/i-croc).

Since 2018, she participates to an INCA project aiming to investigate "the CHCHD4-dependent mitochondrial import machinery and its targeting for cancer therapy".

Since 2014, She is scientific coordinator of the High throughput screening facility, CIBLOT, IPSIT, in faculty of Pharmacy, Chatenay-Malabry, University Paris Sud. The facility belongs to the GDR CNRS Chembioscreen (http://www.chembioscreen.fr/). CIBLOT is included in C@PS (Screening at Paris Saclay) sharing an IBIZA label.

Recently, she received a grant form SFCE to discover novel metaboiic inhibitors for pediatric cancers In collaboration with Dr B. Geoerger, Gustave Roussy, Villejuif, France.

Main achievments: 156 publications, 31 invited oral communications, 27 grants, 5 patents, 14 PhDs, and 7 international meetings organisation.